Expecting to improve its odds of success for the experimental heart drug darapladib, a top drug prospect that failed its first late-stage test, investigators at GlaxoSmithKline have changed up the primary endpoint in the remaining Phase III study that reads out later this quarter.

…read more

Source: GlaxoSmithKline ups odds on heart drug hopeful with a changeup in endpoints


0 No comments